Multaq Liver Damage Lawsuit | Multaq Liver Failure Lawyer

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Bookmark and Share  
01/14/2012 - Allergies to Plavix®, also know by its chemical name, Clopidogrel occur in about six percent of patients given the drug, vital for the prevention of life-threatening stent thrombosis after angioplasty and percutaneous coronary interventions. Researchers at Thomas Jefferson University found that a combination of steroids and antihistamines can successfully alleviate the allergic reaction and enable patients to remain on the drug. Until now, hypersensitivity required drug interruption, placing the patient at risk for restenosis or a major coronary event.
01/12/2012 - Plavix is prescribed each month to millions of Americans with heart disease. The blood clotting drug is the number two heart pill in the world, behind Lipitor, but it doesn't work for everyone. Dr. Charles Mayes, a Cardiologist at Wesley Medical Center said, "We know that about 30% of the population has some element of resistance to Plavix. They don't get the full anti-coagulation or blood thinning effect."
01/11/2012 - There's no need to perform a certain genetic test before deciding whether to prescribe the anti-clotting drug clopidogrel (Plavix), according to a new study published in the Journal of the American Medical Association. However, doctors at Scripps Health who have pioneered the use of this test say Plavix testing is indeed helpful in preventing heart attacks and deaths in coronary stent patients, and that the JAMA study is flawed.
01/04/2012 - A recent study conducted by the National Institute of Neurological Disorders (NINDS) to determine if Plavix-aspirin therapy could prevent recurring strokes in people who had recently suffered subcortical strokes was halted after patients on Plavix-aspirin therapy suffered a higher-than-expected number of bleeding events compared to subjects taking aspirin alone. The Plavix-Aspirin arm involved 3,000 patients.
12/29/2011 - A new study, which was published December 27 in the Journal of the American Medical Association (JAMA), challenged the Food and Drug Administration’s (FDA) “black box” warning for the drug while also casting doubt on the usefulness of a genetic test for taking clopidogrel (Plavix), which is marketed by Bristol-Myers Squibb Co. and Sanofi SA.
06/03/2009 - CHICAGO - Heart patients are often given two or three different drugs to prevent life-threatening blood clots but these combinations can double, triple or even quadruple the risk of stomach or intestinal bleeding, U.S. researchers said on Tuesday.

More Plavix Side Effects News::
Sign up for our FREE email news alerts:
Email address:
Plavix Side Effects Lawsuit

Plavix Side Effects Lawsuit

Bookmark and Share  

What is Plavix?

PLAVIX (Clopidogrel) is a prescription medicine that when taken daily can help reduce your risk of having a future heart attack or stroke. It is recommended for people who have suffered from a recent heart attack or recent stroke, or who have been diagnosed with peripheral artery disease, or P.A.D.—poor circulation in the legs that may cause pain during exercise, such as walking, and may be relieved by rest.

PLAVIX, taken with aspirin, is also recommended for people who have been hospitalized with heart-related chest pain or had a certain type of heart attack (non–Q-wave MI)—conditions doctors call Acute Coronary Syndrome (ACS).

PLAVIX helps keep platelets in the blood from sticking together and forming clots, which helps keep your blood flowing. This helps protect you from a future heart attack or stroke.

Plavix Side Effects

Clopidogrel (Plavix) plus low-dose aspirin reduces cardiovascular events and deaths in patients with vascular disease compared with aspirin alone, a new study confirms. The study, which clarifies when to use dual antiplatelet therapy, reveals that Plavix (clopidogrel) does not provide the same benefit for patients with risk factors but no documented disease.

The CHARISMA (clopidogrel - Plavix - for high atherothrombotic risk and ischemic stabilization management and avoidance) study randomised 15,603 patients with previous cardiovascular or peripheral arterial disease or multiple risk factors to daily clopidogrel (Plavix) (75 mg) or placebo, plus aspirin (75–162mg). Results were reported at the American College of Cardiology annual scientific session in Atlanta, Georgia, this week and online in The New England Journal of Medicine (12 March).

They show the rate of myocardial infarction, stroke, or death from cardiovascular causes in the subgroup of more than 12,000 patients with established vascular disease was reduced by 12.5 per cent (6.9 per cent with clopidogrel versus 7.9 per cent with placebo; P=0.046) after a median follow-up of 28 months. However, patients with risk factors but no documented disease showed no reduction, with a trend to increased risk of events (6.6 per cent with clopidogrel versus 5.5 per cent with placebo; P=0.20). This dichotomy meant that results for the entire group did not reach significance (6.8 per cent versus 7.3 per cent; P=0.22).

The lead investigator, Deepak Bhatt, Cleveland Clinic, Ohio, said: “The findings confirmed previous studies showing benefit with clopidogrel plus aspirin in patients with symptomatic atherothrombosis but showed the potential harm outweighed the benefit in those who only had risk factors.”

  • In 2003 the FDA required label changes to the Plavix patient information insert stating that Plavix increased the risk of intracranial bleeding, GI (gastrointestinal bleeding), ulcerative colitis, lycophytic colitis, strokes, and heart attacks.

  • PLAVIX is contraindicated in patients with active pathologic bleeding such as peptic ulcer or intracranial hemorrhage. PLAVIX should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery, or coadministration with NSAIDs or warfarin.

  • The rates of major and minor bleeding were higher in patients treated with PLAVIX plus aspirin compared with placebo plus aspirin in a clinical trial.

  • As part of the worldwide post marketing experience with PLAVIX, there have been cases of reported thrombotic thrombocytopenic purpura (TTP), some with fatal outcome. TTP has been reported rarely following use of PLAVIX, sometimes after a short exposure (<2 weeks). TTP is a serious condition that can be fatal and requires urgent treatment including plasmapheresis (plasma exchange).

  • In clinical trials, the most common clinically important side effects were pruritus, purpura, diarrhea, and rash; infrequent events included intracranial hemorrhage (0.4 percent) and severe neutropenia (0.05 percent).

If you or a loved one have have taken Plavix - Clopidogrel and have experienced any of the Plavix side effects listed above you may be entitled to compensation. For more information regarding the Plavix litigation or a possible Plavix class action lawsuit contact our Plavix Lawyer today. Fill out our online case evaluation form on this page or call us toll free at: 1.800.856.6405 for your free, confidential case evaluation.

Under no circumstances should you discontinue taking any medication, including Plavix, without first consulting with your doctor.



Required fields in Red:
Mailing Address:
Zip Code:
Please List The Drug, Medical Device or Defective Product You Are Inquiring About:
Please List Any Side Effects, Injuries, or Property Damage:
Additional Information:



Washington DC Office
1101 Pennsylvania Ave.
Suite 600
Washington, DC 20004
Phone: 202.756.2972

Miami Office
1111 Brickell Avenue
11th Floor
Miami, FL 33131
Phone: 305.913.7199

Fort Lauderdale Office
110 E. Broward Blvd.
Suite 1700
Fort Lauderdale, FL 33301
Phone: 954.315.3934
Fax: 954.315.3914






©2010 Ennis & Ennis, P.A. All rights reserved.